The cyclin-dependent kinase 4/6 inhibitor trilaciclib (Cosela) is the first in its class to receive FDA approval as a protective agent against bone marrow loss from treatment for small cell lung ...

RESEARCH TRIANGLE PARK, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today described recently presented real-world data that ...

A novel drug that offers multilineage protection from chemotherapy-induced myelosuppression has been approved by the US Food and Drug Administration. The drug, trilaciclib (Cosela, G1 Therapeutics) is ...

Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center A major adverse effect arising from nimustine ...

The approval was based on data from 3 randomized, placebo-controlled trials that included 245 adults with ES-SCLC. G1 Therapeutics announced the availability of Cosela ™ (trilaciclib) to decrease the ...

Please provide your email address to receive an email when new articles are posted on . Nearly two-thirds of patients had grade 3 or higher myelosuppressive episodes after chemotherapy for ...

The global sales of chemotherapy-induced myelosuppression treatment are projected to witness significant expansion, with revenue estimated at USD 9.52 billion in 2025 and expected to reach USD 15.66 ...

Background. A 50-year-old man who had received a simultaneous pancreas and kidney transplant 9 years earlier developed pancytopenia 3 weeks after starting azathioprine therapy to treat worsening ...

Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center A major adverse effect arising from nimustine ...